Pardes Biosciences Reports First Quarter 2023 Financial
CARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended...
Source: globenewswire.com
Parde Annual Report News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Parde Annual Report. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Parde Annual Report Today - Breaking & Trending Today
Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1... | September 13, 2022
Source: marketscreener.com
Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
CARLSBAD, Calif., Aug. 15, 2022 -- Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and... | August 15, 2022
Source: marketscreener.com